Holen Sie sich die Stockscreener-App
322.28
0.22%
-0.70
Handel nachbörslich:
322.00
-0.28
-0.09%
Schlusskurs vom Vortag:
$322.98
Offen:
$322.14
24-Stunden-Volumen:
1.58M
Relative Volume:
1.10
Marktkapitalisierung:
$42.58B
Einnahmen:
$3.21B
Nettoeinkommen (Verlust:
$43.57M
KGV:
1,340.04
EPS:
0.2405
Netto-Cashflow:
$221.36M
1W Leistung:
-8.43%
1M Leistung:
-19.08%
6M Leistung:
-25.91%
1J Leistung:
+19.81%
1-Tages-Spanne:
$317.80
$325.04
1-Wochen-Bereich:
$317.80
$350.50
52-Wochen-Spanne:
$205.87
$495.55
Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile
Firmenname
Alnylam Pharmaceuticals Inc
Sektor
Branche
Telefon
(617) 551-8200
Adresse
675 WEST KENDALL STREET, CAMBRIDGE, MA
Compare ALNY vs VRTX, REGN, ARGX, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALNY
Alnylam Pharmaceuticals Inc
|
322.28 | 42.67B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
VRTX
Vertex Pharmaceuticals Inc
|
461.24 | 117.59B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
778.97 | 79.81B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
834.55 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
351.27 | 39.11B | 4.98B | 69.60M | 525.67M | 0.5198 |
Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-28 | Fortgesetzt | Barclays | Overweight |
| 2026-01-07 | Fortgesetzt | Oppenheimer | Outperform |
| 2025-08-04 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2025-08-04 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2025-07-30 | Fortgesetzt | Raymond James | Outperform |
| 2025-07-21 | Eingeleitet | Truist | Buy |
| 2025-03-31 | Eingeleitet | Redburn Atlantic | Buy |
| 2025-03-24 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-11-12 | Herabstufung | Wolfe Research | Peer Perform → Underperform |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-08-16 | Hochstufung | Goldman | Neutral → Buy |
| 2024-02-16 | Herabstufung | Goldman | Buy → Neutral |
| 2024-02-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2023-12-08 | Eingeleitet | Wells Fargo | Equal Weight |
| 2023-10-11 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2023-09-29 | Eingeleitet | Raymond James | Outperform |
| 2023-05-05 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-26 | Eingeleitet | SMBC Nikko | Neutral |
| 2023-03-21 | Eingeleitet | Bernstein | Outperform |
| 2023-01-18 | Eingeleitet | Canaccord Genuity | Buy |
| 2022-09-09 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2022-06-27 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-06-07 | Eingeleitet | William Blair | Outperform |
| 2022-04-25 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-03-01 | Eingeleitet | Citigroup | Buy |
| 2022-02-03 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-01-03 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-11-22 | Hochstufung | Goldman | Neutral → Buy |
| 2021-11-22 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-01 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-10-04 | Hochstufung | UBS | Neutral → Buy |
| 2021-08-04 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-02-22 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-02-12 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-02-12 | Bestätigt | H.C. Wainwright | Buy |
| 2021-01-25 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-30 | Fortgesetzt | Berenberg | Hold |
| 2020-09-08 | Eingeleitet | Citigroup | Buy |
| 2020-08-11 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2020-05-13 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2020-05-07 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-04-24 | Fortgesetzt | Evercore ISI | Outperform |
| 2020-03-19 | Eingeleitet | Berenberg | Buy |
| 2019-12-19 | Bestätigt | Chardan Capital Markets | Buy |
| 2019-11-20 | Eingeleitet | Oppenheimer | Outperform |
| 2019-11-13 | Eingeleitet | BofA/Merrill | Buy |
| 2019-05-23 | Fortgesetzt | Goldman | Neutral |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2019-03-06 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2019-03-05 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2019-01-23 | Eingeleitet | UBS | Neutral |
| 2018-10-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-08-13 | Bestätigt | Stifel | Buy |
| 2018-08-07 | Hochstufung | Stifel | Hold → Buy |
| 2018-05-04 | Bestätigt | Stifel | Hold |
| 2018-03-28 | Eingeleitet | Evercore ISI | In-line |
Alle ansehen
Alnylam Pharmaceuticals Inc Aktie (ALNY) Neueste Nachrichten
Alnylam earnings ahead: Can blockbuster TTR drug deliver? By Investing.com - Investing.com Canada
Will Alnylam Pharmaceuticals Inc. stock return to pre crisis levels2025 Price Momentum & Stepwise Entry/Exit Trade Alerts - mfd.ru
Envestnet Asset Management Inc. Has $54.25 Million Holdings in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Countdown to Alnylam (ALNY) Q4 Earnings: A Look at Estimates Beyond Revenue and EPS - Yahoo Finance
Does Alnylam Pharmaceuticals (NASDAQ:ALNY) Have A Healthy Balance Sheet? - Yahoo Finance
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Down 34% From All-Time Highs, Can Alnylam Pharmaceuticals Stock Finally Recover In 2026? - TIKR.com
Alnylam Pharmaceuticals (ALNY) Investor Outlook: Unpacking A 46.21% Potential Upside - DirectorsTalk Interviews
Do options traders know something about Alnylam Pharmaceuticals stock we don't? - MSN
Alnylam Heart Drug Approval Sets Up Challenge With Pfizer - MSN
Insider Trends: Should value investors consider Alnylam Pharmaceuticals Inc2025 AllTime Highs & Risk Controlled Stock Pick Alerts - baoquankhu1.vn
Do Options Traders Know Something About Alnylam Pharmaceuticals Stock We Don't? - TradingView
Alnylam Pharmaceuticals (ALNY) Earnings Expected to Grow: Should You Buy? - Finviz
Allianz Asset Management GmbH Decreases Stock Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam Pharmaceuticals, Inc. $ALNY Shares Acquired by Hantz Financial Services Inc. - MarketBeat
Is There An Opportunity With Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) 49% Undervaluation? - Yahoo Finance
A Look At Alnylam Pharmaceuticals (ALNY) Valuation After New Revenue Outlook And Long Term Growth Targets - simplywall.st
Alnylam Pharmaceuticals (BIT:1ALNY) Price Target Decreased by 11.40% to 411.81 - Nasdaq
Alnylam Pharmaceuticals (ALNY): Investor Outlook with a 41% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Should You Buy Alnylam Pharmaceuticals Before Feb. 12? - AOL.com
25,451 Shares in Alnylam Pharmaceuticals, Inc. $ALNY Purchased by Mediolanum International Funds Ltd - MarketBeat
Analyst Views Diverge as Alnylam Pharmaceuticals, Inc. (ALNY) Targets $5.1B Revenue and Long-Term Growth - Insider Monkey
Alnylam Pharmaceuticals (ALNY) Valuation Check After Recent Share Price Weakness - Yahoo Finance
Alnylam Pharmaceuticals (ALNY) Receives Analyst Rating Update fr - GuruFocus
Has The Recent Pullback In Alnylam Pharmaceuticals (ALNY) Opened A Valuation Opportunity? - simplywall.st
Morgan Stanley Issues Pessimistic Forecast for Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Price - MarketBeat
ALNY: Morgan Stanley Adjusts Price Target Amidst Equal-Weight Ra - GuruFocus
H.C. Wainwright raises Alnylam Pharmaceuticals stock price target on TTR franchise potential - Investing.com Canada
Bank of America Issues Pessimistic Forecast for Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Price - MarketBeat
Alnylam Pharmaceuticals (NASDAQ:ALNY) Given New $510.00 Price Target at HC Wainwright - MarketBeat
HC Wainwright & Co. Maintains Buy Rating on ALNY, Lowers Price T - GuruFocus
Alnylam Pharmaceuticals projects 2026 revenue around $5.3 billion as it focuses on a new five-year strategy - MSN
What analysts say about Alnylam Pharmaceuticals Inc. stockGold Moves & Safe Swing Trade Setups - Mfd.ru
Alnylam Pharmaceuticals Projects 2026 Revenue Around $5.3 Billion as It Focuses on a New Five-Year Strategy - Finviz
What Alnylam Pharmaceuticals (ALNY)'s Analyst Re-Rating on Amvuttra and Pipeline Prospects Means For Shareholders - simplywall.st
Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2025 Financial Results - Business Wire
Whale Trades: Should I hold or sell Alnylam Pharmaceuticals Inc nowWeekly Profit Summary & Long Hold Capital Preservation Plans - baoquankhu1.vn
Barclays Initiates Coverage on Alnylam Pharmaceuticals (ALNY) wi - GuruFocus
Street Watch: Does Alnylam Pharmaceuticals Inc have a sustainable dividendQuarterly Investment Review & Stock Portfolio Risk Control - baoquankhu1.vn
J. Safra Sarasin Holding AG Has $4.34 Million Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam Pharmaceuticals (NASDAQ:ALNY) Earns Overweight Rating from Analysts at Barclays - MarketBeat
Alnylam Pharmaceuticals (NASDAQ:ALNY) Fits the 'Affordable Growth' GARP Profile - Chartmill
Federated Hermes Inc. Boosts Holdings in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam Pharmaceuticals Q4 2025 Earnings Outlook - Intellectia AI
Wells Fargo Raises Alnylam (ALNY) Revenue Estimates for Amvuttra Despite Projected Margin Compression - Finviz
Aug Shorts: Is Alnylam Pharmaceuticals Inc impacted by rising rates2025 Earnings Impact & Safe Investment Capital Preservation Plans - baoquankhu1.vn
EFG Asset Management North America Corp. Trims Stock Holdings in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
What are analysts’ price targets for Alnylam Pharmaceuticals Inc.Weekly Gains Summary & Stepwise Entry and Exit Trade Signals - mfd.ru
The Five Minute Read - Lowell Sun
Mitsubishi UFJ Trust & Banking Corp Sells 8,273 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Wealth Enhancement Advisory Services LLC Boosts Holdings in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Finanzdaten der Alnylam Pharmaceuticals Inc-Aktie (ALNY)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.61%
0.17%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):